News
Browse lab milestones by year, from publications and press coverage to clinical trial launches, talks, and team achievements.
Nadeem goes on a head and neck cancer podcast to discuss recent findings published in Nature Cancer on how intra-tumor bacteria influence the combination of immunotherapy with radiotherapy.
Postdoctoral fellow Shu Yazaki receives a Uehara Memorial Foundation Research Fellowship in recognition of his research contributions.
New Nat Cancer study links intratumoral microbiome and tumor ecosystem features with response and resistance to immune checkpoint blockade plus chemoradiotherapy in head and neck cancer.
ASTROnews publishes “Winter Is Coming: The Changing Landscape of Head & Neck Cancer Biomarkers” by N. Riaz & B. Chera—a reader-friendly overview of precision biomarkers.
Bioengineer.org spotlights our analysis linking lymphocyte preservation to better outcomes—supporting dose and volume de-escalation for HPV-positive disease.
MSK launches a personalized 3-week chemoradiation protocol (FMISO-selected) versus standard 7-week CRT for HPV-positive OPC, listing Dr. Riaz as co-PI.
Postdoctoral fellow Shu Yazaki reports in JCO Precision Oncology on using AlphaMissense to classify DDR-associated mutations across cancer cohorts.
A new NCI award will support Riaz Lab and Tim Chan in studying how homologous recombination repair pathway mutations and related genetic mechanisms shape anti-tumor immunity and immunotherapy efficacy.
JITC publishes a new Riaz Lab study mapping the cold immunological landscape of ATM-deficient cancers and its implications for DDR-directed immunotherapy strategies.
MSK opens trial 25-040: reduced-dose (30 Gy/3 weeks) CRT with adaptive escalation based on early response, listing Dr. Riaz as co-investigator.
The Imaging and Radiation Sciences Program at MSK awarded Riaz Lab and Dr. Yao Yu support for a new project studying how the microbiome shapes head and neck cancer biology.
Nature Medicine publishes a study defining neoantigen immunogenicity landscapes and the evolution of tumor ecosystems during immunotherapy with nivolumab.
Yingjie Zhu first-authors a Genome Medicine paper showing large-scale copy-number alterations are enriched for synthetic viability in BRCA1/BRCA2 tumors, advancing the lab's HRD work.
Clinical Cancer Research reports genotype-directed synthetic cytotoxicity between ATR inhibition and radiotherapy, highlighting a rational strategy for ATM-deficient tumors.
IJROBP reports increased synthetic cytotoxicity from combinatorial chemoradiation in homologous recombination-deficient tumors, extending the lab's translational DDR-radiotherapy program.
The Journal of Clinical Oncology publishes the marquee hypoxia-directed treatment study in HPV-related oropharyngeal carcinoma, a clinical anchor for the lab's precision radiotherapy program.
The Lancet publishes the CURB phase 2 trial evaluating standard systemic therapy with or without stereotactic body radiotherapy in oligoprogressive breast and non-small-cell lung cancer.
